Vaxcyte amends HQ lease to 258,581 RSF, subleases 16,731 SF to Iovance Biotherapeutics

Vaxcyte, Inc.

Amended lease expands premises from ~113k to 258,581 RSF across floors 1-6, phased move-ins Feb 2025 through June 2026.
Initial base rent $5.941-$6.026/RSF/month for existing premises; $6.00/RSF for additional; 8-month abatement, 3% annual escalations.
Lease term 120 months from first additional premises commencement, with two 5-year renewal options.
Subleased 16,731 RSF of Suite 100A to Iovance Biotherapeutics for 2 years at $5.95/RSF, rising to $6.1285/RSF after year one.
Security deposit of ~$1.09M in letters of credit carried over from prior leases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.